Novel targets and therapeutic strategies for type 2 diabetes

被引：52

作者：

Morral, N ^{[1
]}

机构：

[1] Mt Sinai Sch Med, Carl C Icahn Ctr Gene Therapy & Mol Med, New York, NY 10029 USA

来源：

TRENDS IN ENDOCRINOLOGY AND METABOLISM | 2003年 / 14卷 / 04期

基金：

美国国家卫生研究院;

关键词：

D O I：

10.1016/S1043-2760(03)00031-6

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The number of people diagnosed with type 2 diabetes mellitus (T2DM) is increasing at an alarming rate in western societies and has become a major health concern. During the past decade, studies using transgenic animals, gene transfer and pharmacological agents have yielded many data that have helped understand the molecular alterations characteristic of T2DM. This has opened the possibility for the development of potentially more-effective therapies, mainly focused on attenuating hepatic glucose production, enhancing glucose-dependent insulin secretion, enhancing the insulin signal transduction pathway, inhibiting lipolysis from the adipose tissue and promoting fatty acid oxidation.

引用

页码：169 / 175

页数：7

共 69 条

[1] Alterations in skeletal muscle protein-tyrosine phosphatase activity and expression in insulin-resistant human obesity and diabetes [J].

Ahmad, F ;

Azevedo, JL ;

Cortright, R ;

Dohm, GL ;

Goldstein, BJ .

JOURNAL OF CLINICAL INVESTIGATION, 1997, 100 (02) :449-458

[2] Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes [J].

Ahrén, B ;

Simonsson, E ;

Larsson, H ;

Landin-Olsson, M ;

Torgeirsson, H ;

Jansson, PA ;

Sandqvist, M ;

Båvenholm, P ;

Efendic, S ;

Eriksson, JW ;

Dickinson, S ;

Holmes, D .

DIABETES CARE, 2002, 25 (05) :869-875

[3] Chlorogenic acid and hydroxynitrobenzaldehyde: New inhibitors of hepatic glucose 6-phosphatase [J].

Arion, WJ ;

Canfield, WK ;

Ramos, FC ;

Schindler, PW ;

Burger, HJ ;

Hemmerle, H ;

Schubert, G ;

Below, P ;

Herling, AW .

ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1997, 339 (02) :315-322

[4] The adipocyte-secreted protein Acrp30 enhances hepatic insulin action [J].

Berg, AH ;

Combs, TP ;

Du, XL ;

Brownlee, M ;

Scherer, PE .

NATURE MEDICINE, 2001, 7 (08) :947-953

[5] Peroxisome proliferator-activated receptor-γ ligands inhibit adipocyte 11β-hydroxysteroid dehydrogenase type 1 expression and activity [J].

Berger, J ;

Tanen, M ;

Elbrecht, A ;

Hermanowski-Vosatka, A ;

Moller, DE ;

Wright, SD ;

Thieringer, R .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (16) :12629-12635

[6] Effect of 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside infusion on in vivo glucose and lipid metabolism in lean and obese Zucker rats [J].

Bergeron, R ;

Previs, SF ;

Cline, GW ;

Perret, P ;

Russell, RR ;

Young, LH ;

Shulman, GI .

DIABETES, 2001, 50 (05) :1076-1082

[7] Encapsulated, genetically engineered cells, secreting glucagon-like peptide-1 for the treatment of non-insulin-dependent diabetes mellitus [J].

Burcelin, R ;

Rolland, E ;

Dolci, W ;

Germain, S ;

Carrel, V ;

Thorens, B .

BIOARTIFICIAL ORGANS II: TECHNOLOGY, MEDICINE, AND MATERIALS, 1999, 875 :277-285

[8] Elucidation of the role of fructose 2,6-bisphosphate in the regulation of glucose fluxes in mice using in vivo 13C NMR measurements of hepatic carbohydrate metabolism [J].

Choi, IY ;

Wu, C ;

Okar, DA ;

Lange, AJ ;

Gruetter, R .

EUROPEAN JOURNAL OF BIOCHEMISTRY, 2002, 269 (18) :4418-4426

[9] The lipid phosphatase SHIP2 controls insulin sensitivity [J].

Clément, S ;

Krause, U ;

Desmedt, F ;

Tanti, JF ;

Behrends, J ;

Pesesse, X ;

Sasaki, T ;

Penninger, J ;

Doherty, M ;

Malaisse, W ;

Dumont, JE ;

Le Marchand-Brustel, Y ;

Erneux, C ;

Hue, L ;

Schurmans, S .

NATURE, 2001, 409 (6816) :92-97

[10] Effects of a novel glycogen synthase kinase-3 inhibitor on insulin-stimulated glucose metabolism in Zucker diabetic fatty (falfa) rats [J].

Cline, GW ;

Johnson, K ;

Regittnig, W ;

Perret, P ;

Tozzo, E ;

Xiao, L ;

Damico, C ;

Shulman, GI .

DIABETES, 2002, 51 (10) :2903-2910

← 1 2 3 4 5 6 7 →